Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marja-Riitta Taskinen

Showing results (131-140 of 230) with videos related to

Pageof 23
Sort By:
International Journal of Cardiology|July 20, 2014
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trialEli M Roth, Marja-Riitta Taskinen, Henry N Ginsberg, et al.
European Journal of Preventive Cardiology|February 25, 2020
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumabAntonio J Vallejo-Vaz, Lawrence A Leiter, Stefano Del Prato, et al.
Diabetologia|September 29, 2023
Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapyMarja-Riitta Taskinen, Niina Matikainen, Elias Björnson, et al.
European Journal of Endocrinology|September 12, 2009
Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjectsVincenzo Di Marzo, An Verrijken, Antti Hakkarainen, et al.
NMR in Biomedicine|January 11, 2007
1H NMR metabonomics of plasma lipoprotein subclasses: elucidation of metabolic clustering by self-organising mapsTeemu Suna, Aino Salminen, Pasi Soininen, et al.
Diabetes Research and Clinical Practice|March 13, 2024
Not enough known about fenofibrate's kidney effects in people with Type 2 diabetesAlicia J Jenkins, Rachel L O'Connell, Andrzej S Januszewski, et al.
The Journal of Clinical Endocrinology and Metabolism|March 13, 2015
Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variantRosellina M Mancina, Niina Matikainen, Cristina Maglio, et al.
Cardiovascular Diabetology|November 23, 2011
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trialRussell Scott, Mark Donoghoe, Gerald F Watts, et al.
Journal of the American College of Cardiology|December 20, 2008
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitusAnne Hiukka, Jukka Westerbacka, Eeva S Leinonen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 29, 2015
Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic StudyJan Borén, Gerald F Watts, Martin Adiels, et al.
Pageof 23

Showing results (131-140 of 230) with videos related to

Sort By:
Pageof 23
International Journal of Cardiology|July 20, 2014
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trialEli M Roth, Marja-Riitta Taskinen, Henry N Ginsberg, et al.
European Journal of Preventive Cardiology|February 25, 2020
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumabAntonio J Vallejo-Vaz, Lawrence A Leiter, Stefano Del Prato, et al.
Diabetologia|September 29, 2023
Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapyMarja-Riitta Taskinen, Niina Matikainen, Elias Björnson, et al.
European Journal of Endocrinology|September 12, 2009
Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjectsVincenzo Di Marzo, An Verrijken, Antti Hakkarainen, et al.
NMR in Biomedicine|January 11, 2007
1H NMR metabonomics of plasma lipoprotein subclasses: elucidation of metabolic clustering by self-organising mapsTeemu Suna, Aino Salminen, Pasi Soininen, et al.
Diabetes Research and Clinical Practice|March 13, 2024
Not enough known about fenofibrate's kidney effects in people with Type 2 diabetesAlicia J Jenkins, Rachel L O'Connell, Andrzej S Januszewski, et al.
The Journal of Clinical Endocrinology and Metabolism|March 13, 2015
Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variantRosellina M Mancina, Niina Matikainen, Cristina Maglio, et al.
Cardiovascular Diabetology|November 23, 2011
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trialRussell Scott, Mark Donoghoe, Gerald F Watts, et al.
Journal of the American College of Cardiology|December 20, 2008
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitusAnne Hiukka, Jukka Westerbacka, Eeva S Leinonen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 29, 2015
Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic StudyJan Borén, Gerald F Watts, Martin Adiels, et al.
Pageof 23